Literature DB >> 8523091

Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?

B P O'Neill1, R P Dinapoli, P J Kurtin, T M Habermann.   

Abstract

OBJECTIVE: To demonstrate the extent of staging necessary to exclude occult systemic stage IV NHL before making a diagnosis of stage I AE PCNSL.
BACKGROUND: The diagnosis of PCNSL requires the demonstration of malignant lymphocytes within the CNS (usually by biopsy) and finding no evidence of systemic NHL. Different staging approaches have been recommended, ranging from extensive systemic evaluation (including bone marrow examination) to a more focused approach (abdominal and pelvic CT) to no systemic evaluation. We have employed a staging regimen that included: ophthalmologic evaluation (including slit lamp examination); CT of chest, abdomen, and pelvis; bilateral iliac crest aspirate and biopsy; flow cytometry of circulating lymphocytes; and, in men, testicular ultrasound. DESIGN/
METHODS: We carried out a retrospective review of 128 patients entered into the Mayo Lymphoma Project data bank (1975-1994).
RESULTS: Between the years 1975 and 1994, five patients (3.9%) were identified who fulfilled criteria for the diagnosis of PCNSL (typical clinical history, pathognomonic neuro-imaging, and histologic proof of NHL in brain tissue) but who had occult systemic NHL on staging (bone marrow 1, abdominal lymph nodes 3), or at autopsy (colon 1). Case histories are presented.
CONCLUSIONS: Patients with apparent PCNSL may have systemic NHL. Complete staging is essential to the initial management of patients presenting as PCNSL to exclude systemic stage IV disease.

Entities:  

Mesh:

Year:  1995        PMID: 8523091     DOI: 10.1007/bf01054724

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.

Authors:  D F Nelson; K L Martz; H Bonner; J S Nelson; J Newall; H D Kerman; J W Thomson; K J Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Diagnosis of primary cerebral lymphoma with particular reference to CT-guided stereotactic biopsy.

Authors:  W Feiden; K Bise; U Steude
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

3.  Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.

Authors:  D C Miller; F H Hochberg; N L Harris; M L Gruber; D N Louis; H Cohen
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

4.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

5.  Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report.

Authors:  D J Stewart; N Russell; E A Atack; A Quarrington; L Stolbach
Journal:  Cancer Treat Rep       Date:  1983-03

Review 6.  Primary central nervous system lymphoma.

Authors:  B P O'Neill; J J Illig
Journal:  Mayo Clin Proc       Date:  1989-08       Impact factor: 7.616

7.  Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy.

Authors:  L M DeAngelis; J Yahalom; M H Heinemann; C Cirrincione; H T Thaler; G Krol
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

8.  The clinical spectrum of ocular lymphoma.

Authors:  K Peterson; K B Gordon; M H Heinemann; L M DeAngelis
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

9.  Central nervous system lymphoma: histologic types and CT appearance.

Authors:  C R Jack; B P O'Neill; P M Banks; D F Reese
Journal:  Radiology       Date:  1988-04       Impact factor: 11.105

Review 10.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

View more
  17 in total

Review 1.  Diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

2.  Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.

Authors:  Rachna Malani; Ankush Bhatia; Julia Wolfe; Christian Grommes
Journal:  Leuk Lymphoma       Date:  2019-01-10

3.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

Review 4.  Primary CNS lymphoma: findings outside the brain.

Authors:  U Herrlinger
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

5.  Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

Authors:  Kristoph Jahnke; Eckhard Thiel; Peter Martus; Ulrich Herrlinger; Michael Weller; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

6.  Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

Authors:  B P O'Neill; T M Habermann; T E Witzig; M Rodriguez
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 7.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

8.  The utility of body FDG PET in staging primary central nervous system lymphoma.

Authors:  Nimish A Mohile; Lisa M Deangelis; Lauren E Abrey
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

Review 9.  A systematic approach to the diagnosis of suspected central nervous system lymphoma.

Authors:  Brian J Scott; Vanja C Douglas; Tarik Tihan; James L Rubenstein; S Andrew Josephson
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

10.  Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.

Authors:  Ramandeep S Arora; Robert D Alston; Tim O B Eden; Edward J Estlin; Anthony Moran; Jillian M Birch
Journal:  Neuro Oncol       Date:  2008-11-24       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.